Retreatment With Radium-223 Found Safe in mCRPC
Wednesday, 1st June 2016
Luke Nordquist, MD, discusses a study investigating a higher dose of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and the ongoing potential of the agent in treating the disease.
This article was picked up by Colin Hubball - thanks Colin !
CANCELLED Group Meeting at Leighton Hospital, Crewe
11 Jul 2020 10:00–12:00
PSA Testing at Delamere Forest Golf Club CANCELLED
3 Oct 2020 09:30–13:00
Look Good Feel Better Men's Skin Care Free Workshop
22 Oct 2020 17:30–20:00